Compare BioNano Genomics Inc (BNGO) vs HP Inc (HPQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs HP Inc — how do they compare? BioNano Genomics Inc trades at $1.24 (market cap $13.66M), while HP Inc trades at $29.19 (market cap $26.59B). The key difference: HP Inc is far larger — about 1946.6× BioNano Genomics Inc's market cap, and HP Inc pays a 4.13% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | HPQ | |
|---|---|---|
Market Cap | $13.66M | $26.59B |
Sector | Health | Technology |
52-Week High | $4.92 | $30.05 |
52-Week Low | $1.06 | $18.20 |
Enterprise Value | $16.26M | $33.75B |
Dividend Yield | — | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
HPQ trades at $28.96, down 2.82% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. Revenue for 2025 reached $55.3 billion, with a net income margin of 4.45%, while valuation metrics like a P/E of 10.77 and P/S of 0.48 suggest potential undervaluation. Recent news highlights AI-driven cost savings and a profitable upgrade cycle, with Q2 FY2026 revenue up 9% year-over-year.
The outlook is mixed; HPQ benefits from solid cash flow and dividend yields near 4%, but faces risks from PC market declines and competitive pressures. Analyst consensus is cautious with a hold-heavy rating, and the stock trades above the consensus price target of $22, indicating limited upside. Investors should weigh steady profitability against industry headwinds and valuation constraints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →
